More articles from PDA Paper

You have access
Currently Available Recombinant Alternatives to Horseshoe Crab Blood Lysates: Are They Comparable for the Detection of Environmental Bacterial Endotoxins? A Review
Jay Bolden, Chris Knutsen, Jack Levin, Catherine Milne, Tina Morris, Ned Mozier, Ingo Spreitzer and Friedrich von Wintzingerode

PDA Journal of Pharmaceutical Science and Technology September 2020, 74 (5) 602-611; DOI: https://doi.org/10.5731/pdajpst.2020.012187
You have access
Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic
T. Cundell, D. Guilfoyle, T. R. Kreil and A. Sawant

PDA Journal of Pharmaceutical Science and Technology July 2020, 74 (4) 468-494; DOI: https://doi.org/10.5731/pdajpst.2020.012021
You have access
Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations
Sylvia Anger, Cecile Begat, Vincent Crnko, GianMaurizio Fantozzi, Wadi Farach, Sean Fitzpatrick, Brian Gallagher, Stefan Huelsmann, Paul Kinsey, Vincent Langlade, Ghislain Lefevre, Elise Legendre, Kevin McLean, Jahanvi Miller, Ravi Patel, Anthony Perry, Herve Soukiassian, Amy Stanton, Dorothee Streich, Christopher Timmons, DAVID Vaneylen, Tony van Hoose, Linda Wildling and Mike Windover

PDA Journal of Pharmaceutical Science and Technology November 2019, 73 (6) 635-647; DOI: https://doi.org/10.5731/pdajpst.2019.010645
You have access
Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management
Anders Vinther and Emma Ramnarine

PDA Journal of Pharmaceutical Science and Technology September 2019, 73 (5) 517-521; DOI: https://doi.org/10.5731/pdajpst.2019.010827
You have access
PDA PAC iAM 2017 Survey on Post Approval Change: Is the Regulatory Environment Hindering Much-Needed Innovation in the Pharma Industry?
Authors: Members of the PDA Task Force Post Approval Changes for Innovation in Availability of Medicines (PAC iAM), Emma Ramnarine, Ursula Busse, Marcello Colao, Julia Edwards, Kara Follman, Karolyn Gale, Kassidy Good, Suzanne Kiani, Maik Jornitz, Morten Munk, Kevin O'Donnel, Melissa Seymour, Mihaela Simianu, Lisa Skeens, Anders Vinther, Denyse Baker and Rich Levy

PDA Journal of Pharmaceutical Science and Technology September 2017, 71 (5) 421-427; DOI: https://doi.org/10.5731/pdajpst.2017.008219
You have access
PDA Points To Consider: Fundamental Concepts in Data Integrity
Bob Buhlmann, Madlene Dole and Zena Kaufmann

PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062
You have access
Quality Culture Survey Report
Pritesh Patel, Denyse Baker, Rick Burdick, Cylia Chen, Jonathon Hill, Morgan Holland and Anil Sawant

PDA Journal of Pharmaceutical Science and Technology September 2015, 69 (5) 631-642; DOI: https://doi.org/10.5731/pdajpst.2015.01078
You have access
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products
Stan Bukofzer, John Ayres, Anna Chavez, Minerva Devera, Jahanvi Miller, Douglas Ross, John Shabushnig, Susan Vargo, Harry Watson and Rick Watson

PDA Journal of Pharmaceutical Science and Technology January 2015, 69 (1) 123-139; DOI: https://doi.org/10.5731/pdajpst.2015.01037
You have access
PARENTERAL DRUG ASSOCIATION POINTS TO CONSIDER: Pharmaceutical Quality Metrics Updated September 2014
PDA June 2014 Definitions Task Force and December 2013 Points to Consider Authors, Steve Mendivil, Joyce Bloomfield, Vince Anicetti, Denyse Baker, Ian Elvins, John Farris, Gabriele Gori, Bob Kieffer, Edwin Martinez-Rivera, Marty Nealey, Pritesh Patel, Anil Sawant, Sue Schniepp, Anders Vinther and Glenn Wright

PDA Journal of Pharmaceutical Science and Technology September 2014, 68 (5) 535-545; DOI: https://doi.org/10.5731/pdajpst.2014.01021

Main menu

User menu

Search

More articles from PDA Paper

Readers

Author/Reviewer Information

Parenteral Drug Association, Inc.